Genomic technologies offer the promise of a comprehensive understanding of cancer.
These technologies are being used to characterize tumours at the molecular level, and
several clinical successes have shown that such information can guide the design of drugs
targeted to a relevant molecule. One of the main barriers to further progress is identifying the
biological indicators, or biomarkers, of cancer that predict who will benefit from a particular
targeted therapy.